Please try another search
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Ramy A. Mahmoud | 59 | 2010 | CEO & Director |
Catherine E. Owen | 53 | 2020 | Independent Director |
Wilhelmus C. M. Groenhuysen | 66 | 2017 | Independent Director |
Eric Bednarski | - | 2021 | Independent Director |
Sandra Lynn Helton | 74 | 2018 | Independent Director |
R. John Fletcher | 78 | 2022 | Independent Chairman |
Kyle Dempsey | 35 | 2021 | Independent Director |
Tomas J. Heyman | 68 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review